Merck Sharp + Dohme Corp.

Merck Sharp + Dohme B.v.

Iomet Pharma Ltd.

Hongjun Zhang

Yongxin Han

Kun Liu

Derun Li

Nunzio Sciammetta

Abdelghani Achab

Qinglin Pu

Kenneth Jay Barr

Xavier Fradera

Blair T Lapointe

Hua Zhou

Xianhai Huang

Richard Thomas Beresis

Anandan Palani

Wensheng Yu

David L Sloman

Liangqin Guo

Shuwen He

Purakkattle J Biju

Yongqi Deng

Catherine M White

Peter H Fuller

Meredeth Ann McGowan

Hakan Gunaydin

Neville J Anthony

Jason D Brubaker

Matthew Lloyd Childers

John K MacLean

Joseph A Kozlowski

Alexander Pasternak

Phieng Siliphaivanh

B Wesley Trotter

Joshua Close

Joon Jung

Craig R Gibeau

Mark E Scott

Dane James Clausen

Min Lu

Jared N Cumming

Robert G Aslanian

Kevin D McCormick

Dong Xiao

Li Xiao

Ashwin Umesh Rao

Christian Fischer

Charles A Lesburg

Wei Zhou

Corey E Bienstock

Luis E Torres

Christopher J Dinsmore

Jongwon Lim

Younong Yu

Joey Lee Methot

Christopher W Boyce

Jonathan R Young

Guoqing Li

Robert D Mazzola, Jr

Jason David Katz

Tony Siu

Qin Jiang

David Jonathan Bennett

Feng Ye

Jun Qin

Yuan Tian

Tesfaye Biftu

Ravi P Nargund

Brian Alexander McKittrick

Sung-Sau So

David James Witter

Stephane L Bogen

Kevin J Wilson

Ying Huang

Feroze Ujjainwalla

Zhicai Wu

Michelle R Machacek

David Joseph Guerin

Zhi-Cai Shi

Ryan D Otte

Brian M Andresen

Christopher Francis Thompson

Ping Chen

Norman Kong

Michael Hale Reutershan

Xiao Chen

Feng Shi

John P Caldwell

John W Butcher

Lei Chen

Matthew H Daniels

Matthew Christopher

John W Lampe

Benjamin Wesley Trotter

Haiqun Tang

Min K Park

Vladimir Simov

Pengcheng Patrick Shao

Dann LeRoy Parker, Jr

Francesc Xavier Fradera Llinas

Phillip Martin Cowley

Salem Fevrier

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Arginase inhibitors and methods of use

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases. 

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. 

Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Growing community of inventors

Boston, MA, United States of America

Hongjun Zhang